Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Total Liabilities (2020 - 2025)

Xeris Biopharma Holdings' Total Liabilities history spans 6 years, with the latest figure at $369.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 4.87% year-over-year to $369.8 million, compared with a TTM value of $369.8 million through Dec 2025, up 4.87%, and an annual FY2025 reading of $369.8 million, up 4.87% over the prior year.
  • Total Liabilities for Q4 2025 was $369.8 million at Xeris Biopharma Holdings, roughly flat from $371.1 million in the prior quarter.
  • The five-year high for Total Liabilities was $371.1 million in Q3 2025, with the low at -$44.4 million in Q1 2021.
  • Average Total Liabilities over 5 years is $270.8 million, with a median of $319.5 million recorded in 2023.
  • Year-over-year, Total Liabilities surged 1330.25% in 2022 and then grew 0.85% in 2025.
  • Tracing XERS's Total Liabilities over 5 years: stood at $209.1 million in 2021, then skyrocketed by 43.13% to $299.3 million in 2022, then increased by 10.04% to $329.4 million in 2023, then rose by 7.07% to $352.7 million in 2024, then rose by 4.87% to $369.8 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Total Liabilities are $369.8 million (Q4 2025), $371.1 million (Q3 2025), and $354.0 million (Q2 2025).